Advancing person-centred care across the cardiometabolic spectrum through scientific innovation​

 

Chairs: Chantal Mathieu (BEL) & Zoe Williams (GBR)

09:00 – 09:15Welcome and introduction: intergrating a person-centred approach to cardimetabolic diseasesChantal Mathieu (BEL)
Zoe Williams (GBR)
09:15 – 09:35Broading personal choice in obesity care: injectable and oral semaglutide formulationsCarel Le Roux (IRL)
09:35 – 09:55Raising the bar in T2D care: optimising glucose and weight management with semaglutideHarpreet Bajaj (CAN)
09:55 – 10:10Ahead of the curve: early intervention in obesity strategies for children and adolescentsMartin Wabitsch (GER)
10:10 – 10:20Panel discussion

Carel Le Roux (IRL)
Harpreet Bajaj (CAN)
Martin Wabitsch (GER)

10:20 – 10:40Coffee break 
10:40 – 10:45Welcome backChantal Mathieu (BEL)
Zoe Williams (GBR)
10:45 – 11:55Semaglutide in holistic cardiometabolic care: beyond glycaemia and weight

Katherine Tuttle (USA)
Philip Newsome (GBR)
Erin Bohula (USA)

11:55 – 12:00Session closeChantal Mathieu (BEL)
Zoe Williams (GBR)
12:00 – 12:45Lunch break 
12:45 – 12:50Amylin in focus: framing the scientific journey aheadChantal Mathieu (BEL)
Zoe Williams (GBR)
12:50 – 13:10Amylin: from physiological insights to therapeutic potentialAnna Secher (DNK)
13:10 – 14:05CagriSema: releasing the power of amylin in obesity and T2DKirsi Pietiläinen (FIN)
John Buse (USA)
14:05 – 14:25Expert perspectives: the potential of amylin-based therapies

Kirsi Pietiläinen (FIN)
John Buse (USA)
Anna Secher (DNK)

14:25 – 14:55Zenagamtide: GLP-1 and amylin agonism in one moleculeRoopa Mehta (MEX)
Pablo Mora (USA)
14:55 – 15:05Expert perspectives: future directionsRoopa Mehta (MEX)
Pablo Mora (USA)
15:05 – 15:15Looking ahead: the future of amylin in metabolic diseaseChantal Mathieu (BEL)
Zoe Williams (GBR)
15:15 – 15:45Coffee break 
15:45 Monday to Monday: the once-weekly mindset with insulinsConcetta Irace (ITA)
Harpreet Bajaj (CAN)
15:45Evidence in context: the potential of amylin-based therapiesPablo Mora (USA)
John Buse (USA)
15:45From data to decision-making: practical considerations for GLP-1 therapyCarel Le Roux (IRL)
Roopa Mehta (MEX)
Novo Nordisk logo